← Leaderboards
Michael Lebowitz
Panacea Pharmaceuticals, Inc.
$1,857,000
Attributed
$1,857,000
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2010–11$1M$750K$500K$250K$0
'10
'11
Funding mix
By agency
NIH$1,857,000 · 2
By mechanism
R44$1,750,000 · 1
R43$107,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Fda Approved”
- Thomas Macvittie · University Of Maryland Baltimore$64,108,499
- David H Walker · University Of Texas Medical Br Galveston$61,066,312
- Polly Chang · Sri International$60,528,575
- Henry F Chambers · Duke University$48,458,380
- Robert H Vonderheide · University Of Pennsylvania$48,412,540
- Susan Abushakra · Alzheon, Inc.$47,690,244
Research focus
Fda ApprovedFunctional DisorderAmericanDrug Delivery Systems70-Kda Ribosomal Protein S6 KinasesBiomarkerBiopsyBreast Cancer TreatmentAdjuvant TherapyDiagnostic TestsBaseCharacteristicsClinical ResearchClinical TreatmentClinical TrialsCohortCollegeCommercializationCompanionsBusinessesConsultationsCancer TypeDiagnosticFunding
Grant awards (3)
PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm$1,000,000
R44 · FY2011 · CA · contact PI
PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm$750,000
R44 · FY2010 · CA · contact PI
Alpha-Synuclein: A Drug Target for Parkinson's Disease$107,000
R43 · FY2001 · AG